Table 1 Patients baseline characteristics

Female sex, n (%)

76 (59%)

49 (59%)

33 (49%)

0.320^b

Age, median (IQR)

56 (48 – 62)

60 (50 – 67)

56 (51 – 64)

0.197^a

Comorbidities

 CRS, n (%)

13 (10%)

13 (16%)

4 (6%)

0.143^b

 CRSwNP, n (%)

34 (26%)

16 (19%)

14 (21%)

0.405^b

 Atopic Dermatitis, n (%)

6 (5%)

4 (5%)

21 (31%)

 < 0.001^b

 Allergic Rhinitis, n (%)

4 (3%)

2 (2%)

10 (15%)

0.001^b

 ASS intolerance, n (%)

17 (13%)

7 (8%)

17 (25%)

0.016^b

Asthma phenotype

 Allergic, n (%)

6 (5%)

4 (5%)

5 (7%)

0.020^b

 Eosinophilic, n (%)

98 (76%)

65 (78%)

38 (56%)

 Mixed, n (%)

25 (19%)

14 (17%)

25 (37%)

Smoking status

 never smoked, n (%)

63 (49%)

42 (51%)

36 (53%)

0.812^b

 ex-smoker, n (%)

64 (50%)

41 (49%)

32 (46%)

 Pack years, median (IQR)

0 (0 – 20)

0 (0 – 10)

0 (0 – 6)

0.601^a

Baseline parameters

 ACT score, median (IQR)

13 (10–19)

14 (10–20)

16 (11–19)

0.312^a

 Exacerbations per year, median (IQR)

1 (0 – 2)

1 (0 – 3)

0 (0 – 1)

0.020^a

 OCS-therapy, n (%)

72 (56%)

48 (58%)

29 (43%)

0.095^b

 OCS dose ^c, median (IQR)

5 (0 – 10)

2.5 (0 – 7.5)

0 (0 – 5)

0.347^a

 FEV1% of predicted, median (IQR)

60 (44 – 79)

63 (47 – 80)

64 (48 – 82)

0.910^a

 FVC % of predicted, median (IQR)

82 (70 – 94)

79 (64 – 91)

81 (69 – 95)

0.496^a

 RV % of predicted, median (IQR)

140 (116 – 173)

136 (113 – 159)

134 (112 – 161)

0.290^a

 TLC % of predicted, median (IQR)

105 (95 – 116)

103 (92 – 109)

101 (93 – 112)

0.128^a

 FeNO ppb, median (IQR)

36 (19 – 71.3)

42.1 (24.1 – 65.2)

36 (21.1 – 56.4)

0.332^a

 Blood eosinophils per µl (IQR)

430 (70 – 740)

400 (63 – 678)

220 (70 – 475)

0.301^a